Semaglutide implant clears a first safety trial, with twice-yearly dosing as the goal
Vivani's Phase I SLIM-1 trial tested a low-dose semaglutide implant placed under the skin against weekly low-dose Wegovy in 20 people over four weeks. Every implant went in and came out without complications and there were no treatment-related side effects. The company plans a Phase II weight-maintenance trial in 2027.
Source: Clinical Trials Arena (13 Nov 2026).